Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03706040 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis

A Phase 2 study of Dermatitis, sponsored by AbbVie.

Completed
Registry status
Phase 2
Development phase
172
Enrollment target
20
Study locations

NCT03706040 is a Phase 2 study of Dermatitis that has completed, run by AbbVie. The registered enrollment target is 172 participants, above the 151-participant average among 6 other Dermatitis trials with a reported enrollment target (14% higher). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03706040, a Phase 2 study of Dermatitis, has completed, sponsored by AbbVie.

COMPLETED
Registry status
Phase 2
Development phase
172 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to assess the safety and efficacy of risankizumab for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents.

Conditions Studied

Dermatitis

Interventions

  • BIOLOGICAL Placebo
  • BIOLOGICAL Risankizumab

Study Locations (20)

California

  • Cosmetic Dermatology of Orange County /ID# 205801 - Anaheim
  • Center for Dermatology Clinical Research /ID# 204950 - Fremont
  • Integrative Skin Science and Research /ID# 212486 - Sacramento
  • Cosmetic Laser Dermatology /ID# 210560 - San Diego
  • Therapeutics Clinical Research /ID# 203422 - San Diego

Michigan

  • Oakland Hills Dermatology /ID# 217453 - Auburn Hills
  • Duplicate_Great Lakes Research, Inc. /ID# 206447 - Bay City
  • Grekin Skin Institute /ID# 210485 - Warren

Georgia

  • MetroDerm ACC Research /ID# 205958 - Atlanta
  • Skin Care Physicians of Georgia /ID# 213188 - Macon

Alabama

  • UAB Department of Dermatology /ID# 211561 - Birmingham

Arizona

  • Cognitive Clinical Trials /ID# 208895 - Scottsdale

Colorado

  • Colorado Center for Dermatology, PLLC /ID# 216260 - Centennial

Florida

  • Park Avenue Dermatology, PA /ID# 203378 - Orange Park

Illinois

  • University Dermatology and Vein Clinic, LLC /ID# 210702 - Darien

Trial Details

FieldValue
Enrollment Target 172 participants
Start Date 2018-12-27
Est. Completion 2021-04-26
Phase Phase 2

Sponsor

AbbVie

526 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03706040

The ClinicalTrials.gov registry entry for NCT03706040 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 151-participant average among 6 other Dermatitis trials with a reported enrollment target (14% higher). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03706040 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Michigan, Georgia.

Frequently Asked Questions

What is clinical trial NCT03706040 about?

NCT03706040 is a clinical study titled "A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis". The purpose of this study is to assess the safety and efficacy of risankizumab for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents.

What is the current status of trial NCT03706040?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 172 participants. The study started on 2018-12-27. Estimated completion is 2021-04-26.

What conditions does trial NCT03706040 study?

This clinical trial studies the following conditions: Dermatitis.

What interventions are being tested in trial NCT03706040?

The interventions under investigation include: Placebo (BIOLOGICAL), Risankizumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT03706040?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03706040 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Dermatitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Dermatitis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.